Guest guest Posted August 19, 1999 Report Share Posted August 19, 1999 Steph, This study is the exact same study Patty passed along....??? Were you meaning to send a different one? [eosinophilic gastroenteritis] anotehr study > > > We tried this and it didnt work for us; but here's evidence that it did work > for someone - > > > > > Treatment of eosinophilic gastroenteritis with montelukast > > -------------------------------------------------------------------------- -- > ---- > To the Editor: > > We are reporting what we believe is the first case of a patient successfully > treated with a leukotriene modifier for symptoms related to eosinophilic > gastroenteritis. One of us (C. F.) initially saw a 13-year-old girl for a > 3-year history of progressive nonbilious vomiting. Medical history was > remarkable for allergic rhinitis treated with medications and allergen > immunotherapy but no history of food allergies. Review of previous allergy > skin testing showed absence of reactivity to foods. Her previous allergist > had tried an elimination diet with no symptomatic improvement. A complete > blood cell count showed 574 eosinophils/mL (8% of total neutrophils). The > diagnosis was made by demonstration of marked eosinophilia in biopsy > specimens of the esophagus, gastric antrum, and duodenum and elimination of > other potential etiologies. Stool cultures and a barium esophagram with > small bowel follow through were unremarkable. Symptoms continued despite > treatment with oral cromolyn, ranitidine, and hydroxyzine. Montelukast 10 mg > given orally daily was started, with complete symptom resolution. Follow-up > showed one vomiting episode in 4 months of treatment with montelukast. There > was a decrease in peripheral eosinophilia (574 vs 342 eosinophils/mL) > compared with baseline 2 months after medications were started. Cromolyn, > ranitidine, and hydroxyzine were discontinued with no recurrence of > symptoms. > > Tissue injury in eosinophilic gastroenteritis has been shown to correlate > with the number of activated degranulated eosinophils present.1 Cytokines > including GM-CSF, IL-3, and IL-5 promote eosinophil proliferation and > differentiation in the bone marrow as well as being eosinophil chemotaxins > to sites of inflammation.2 It has been suggested that the release of these > cytokines with autocrine or paracrine activities by eosinophils in the > lamina propria of gastrointestinal tissue may lead to the persistent > eosinophilic infiltration in eosinophilic gastroenteritis.3 Eosinophil > recruitment may also be enhanced by chemotactic factors such as > platelet-activating factor, C-C chemokines, and cysteinyl leukotrienes.2 > Cysteinyl leukotrienes are generated from arachidonic acid through LTC4 > synthase by mast cells, eosinophils, alveolar macrophages, and basophils, > leading to end-organ inflammation.2 LTD4 has been shown to be a potent and > specific chemotactic factor for human eosinophils in vitro, which has been > completely inhibited by a selective leukotriene antagonist.4 Many factors > may play a role in directing eosinophils to a site of inflammation. Because > LTD4 is both produced by and is a chemotactic factor for eosinophils, this > may provide the rationale for treating a patient with eosinophilic > gastroenteritis with a leukotriene receptor antagonist. Further research, > including double-blind placebo-controlled clinical studies, is needed to > clarify the potential role leukotrienes play in the inflammation seen in > eosinophilic gastroenteritis and to assess the potential role for > leukotriene modifiers in the treatment of this disease. > > > > > --------------------------- Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 19, 1999 Report Share Posted August 19, 1999 Dumb me.......I didn't look at where you sent it to. Just looked at it that it came to me. BIG DUH!!! [eosinophilic gastroenteritis] anotehr study > > > > > >> > >> > >> We tried this and it didnt work for us; but here's evidence that it did > >work > >> for someone - > >> > >> > >> > >> > >> Treatment of eosinophilic gastroenteritis with montelukast > >> > >> ------------------------------------------------------------------------- > - > >-- > >> ---- > >> To the Editor: > >> > >> We are reporting what we believe is the first case of a patient > >successfully > >> treated with a leukotriene modifier for symptoms related to eosinophilic > >> gastroenteritis. One of us (C. F.) initially saw a 13-year-old girl for a > >> 3-year history of progressive nonbilious vomiting. Medical history was > >> remarkable for allergic rhinitis treated with medications and allergen > >> immunotherapy but no history of food allergies. Review of previous > allergy > >> skin testing showed absence of reactivity to foods. Her previous > allergist > >> had tried an elimination diet with no symptomatic improvement. A complete > >> blood cell count showed 574 eosinophils/mL (8% of total neutrophils). The > >> diagnosis was made by demonstration of marked eosinophilia in biopsy > >> specimens of the esophagus, gastric antrum, and duodenum and elimination > >of > >> other potential etiologies. Stool cultures and a barium esophagram with > >> small bowel follow through were unremarkable. Symptoms continued despite > >> treatment with oral cromolyn, ranitidine, and hydroxyzine. Montelukast 10 > >mg > >> given orally daily was started, with complete symptom resolution. > >Follow-up > >> showed one vomiting episode in 4 months of treatment with montelukast. > >There > >> was a decrease in peripheral eosinophilia (574 vs 342 eosinophils/mL) > >> compared with baseline 2 months after medications were started. Cromolyn, > >> ranitidine, and hydroxyzine were discontinued with no recurrence of > >> symptoms. > >> > >> Tissue injury in eosinophilic gastroenteritis has been shown to correlate > >> with the number of activated degranulated eosinophils present.1 Cytokines > >> including GM-CSF, IL-3, and IL-5 promote eosinophil proliferation and > >> differentiation in the bone marrow as well as being eosinophil > chemotaxins > >> to sites of inflammation.2 It has been suggested that the release of > these > >> cytokines with autocrine or paracrine activities by eosinophils in the > >> lamina propria of gastrointestinal tissue may lead to the persistent > >> eosinophilic infiltration in eosinophilic gastroenteritis.3 Eosinophil > >> recruitment may also be enhanced by chemotactic factors such as > >> platelet-activating factor, C-C chemokines, and cysteinyl leukotrienes.2 > >> Cysteinyl leukotrienes are generated from arachidonic acid through LTC4 > >> synthase by mast cells, eosinophils, alveolar macrophages, and basophils, > >> leading to end-organ inflammation.2 LTD4 has been shown to be a potent > and > >> specific chemotactic factor for human eosinophils in vitro, which has > been > >> completely inhibited by a selective leukotriene antagonist.4 Many factors > >> may play a role in directing eosinophils to a site of inflammation. > >Because > >> LTD4 is both produced by and is a chemotactic factor for eosinophils, > this > >> may provide the rationale for treating a patient with eosinophilic > >> gastroenteritis with a leukotriene receptor antagonist. Further research, > >> including double-blind placebo-controlled clinical studies, is needed to > >> clarify the potential role leukotrienes play in the inflammation seen in > >> eosinophilic gastroenteritis and to assess the potential role for > >> leukotriene modifiers in the treatment of this disease. > >> > >> > >> > >> > >> --------------------------- ONElist Sponsor ---------------------------- > >> > >> ONElist: home to the world's liveliest email communities. > >> > >> ------------------------------------------------------------------------ > > > > > >--------------------------- Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 19, 1999 Report Share Posted August 19, 1999 Yup, there is! Reading the text of the study made me think a lot about my own condition - no known allergies, scratch tests for food allergies turned up negative, etc. The Singulair seems to be helping - no symptoms now for almost 1 year (Oct). Could one of you provide the source for this study? Steve White -- B. White stephen_white@... " S.J.Harlow " transcription@...> on 08/19/99 11:33:16 AM Please respond to eosinophilic gastroenteritis (AT) onelist (DOT) com To: eosinophilic gastroenteritis (AT) onelist (DOT) com cc: Subject: Re: [eosinophilic gastroenteritis] anotehr study Yes, it's the same on , but she doesnt send to the Eos list and I thought some of these types might like to see it. It might help someone. Actually, I think someone on this list uses Singulair with EG and has some success. Steph Re: [eosinophilic gastroenteritis] anotehr study > > >Steph, > >This study is the exact same study Patty passed along....??? Were you >meaning to send a different one? > > > [eosinophilic gastroenteritis] anotehr study > > >> >> >> We tried this and it didnt work for us; but here's evidence that it did >work >> for someone - >> >> >> >> >> Treatment of eosinophilic gastroenteritis with montelukast >> >> ------------------------------------------------------------------------- - >-- >> ---- >> To the Editor: >> >> We are reporting what we believe is the first case of a patient >successfully >> treated with a leukotriene modifier for symptoms related to eosinophilic >> gastroenteritis. One of us (C. F.) initially saw a 13-year-old girl for a >> 3-year history of progressive nonbilious vomiting. Medical history was >> remarkable for allergic rhinitis treated with medications and allergen >> immunotherapy but no history of food allergies. Review of previous allergy >> skin testing showed absence of reactivity to foods. Her previous allergist >> had tried an elimination diet with no symptomatic improvement. A complete >> blood cell count showed 574 eosinophils/mL (8% of total neutrophils). The >> diagnosis was made by demonstration of marked eosinophilia in biopsy >> specimens of the esophagus, gastric antrum, and duodenum and elimination >of >> other potential etiologies. Stool cultures and a barium esophagram with >> small bowel follow through were unremarkable. Symptoms continued despite >> treatment with oral cromolyn, ranitidine, and hydroxyzine. Montelukast 10 >mg >> given orally daily was started, with complete symptom resolution. >Follow-up >> showed one vomiting episode in 4 months of treatment with montelukast. >There >> was a decrease in peripheral eosinophilia (574 vs 342 eosinophils/mL) >> compared with baseline 2 months after medications were started. Cromolyn, >> ranitidine, and hydroxyzine were discontinued with no recurrence of >> symptoms. >> >> Tissue injury in eosinophilic gastroenteritis has been shown to correlate >> with the number of activated degranulated eosinophils present.1 Cytokines >> including GM-CSF, IL-3, and IL-5 promote eosinophil proliferation and >> differentiation in the bone marrow as well as being eosinophil chemotaxins >> to sites of inflammation.2 It has been suggested that the release of these >> cytokines with autocrine or paracrine activities by eosinophils in the >> lamina propria of gastrointestinal tissue may lead to the persistent >> eosinophilic infiltration in eosinophilic gastroenteritis.3 Eosinophil >> recruitment may also be enhanced by chemotactic factors such as >> platelet-activating factor, C-C chemokines, and cysteinyl leukotrienes.2 >> Cysteinyl leukotrienes are generated from arachidonic acid through LTC4 >> synthase by mast cells, eosinophils, alveolar macrophages, and basophils, >> leading to end-organ inflammation.2 LTD4 has been shown to be a potent and >> specific chemotactic factor for human eosinophils in vitro, which has been >> completely inhibited by a selective leukotriene antagonist.4 Many factors >> may play a role in directing eosinophils to a site of inflammation. >Because >> LTD4 is both produced by and is a chemotactic factor for eosinophils, this >> may provide the rationale for treating a patient with eosinophilic >> gastroenteritis with a leukotriene receptor antagonist. Further research, >> including double-blind placebo-controlled clinical studies, is needed to >> clarify the potential role leukotrienes play in the inflammation seen in >> eosinophilic gastroenteritis and to assess the potential role for >> leukotriene modifiers in the treatment of this disease. >> >> >> >> >> --------------------------- Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 19, 1999 Report Share Posted August 19, 1999 Yes, it's the same on , but she doesnt send to the Eos list and I thought some of these types might like to see it. It might help someone. Actually, I think someone on this list uses Singulair with EG and has some success. Steph Re: [eosinophilic gastroenteritis] anotehr study > > >Steph, > >This study is the exact same study Patty passed along....??? Were you >meaning to send a different one? > > > [eosinophilic gastroenteritis] anotehr study > > >> >> >> We tried this and it didnt work for us; but here's evidence that it did >work >> for someone - >> >> >> >> >> Treatment of eosinophilic gastroenteritis with montelukast >> >> ------------------------------------------------------------------------- - >-- >> ---- >> To the Editor: >> >> We are reporting what we believe is the first case of a patient >successfully >> treated with a leukotriene modifier for symptoms related to eosinophilic >> gastroenteritis. One of us (C. F.) initially saw a 13-year-old girl for a >> 3-year history of progressive nonbilious vomiting. Medical history was >> remarkable for allergic rhinitis treated with medications and allergen >> immunotherapy but no history of food allergies. Review of previous allergy >> skin testing showed absence of reactivity to foods. Her previous allergist >> had tried an elimination diet with no symptomatic improvement. A complete >> blood cell count showed 574 eosinophils/mL (8% of total neutrophils). The >> diagnosis was made by demonstration of marked eosinophilia in biopsy >> specimens of the esophagus, gastric antrum, and duodenum and elimination >of >> other potential etiologies. Stool cultures and a barium esophagram with >> small bowel follow through were unremarkable. Symptoms continued despite >> treatment with oral cromolyn, ranitidine, and hydroxyzine. Montelukast 10 >mg >> given orally daily was started, with complete symptom resolution. >Follow-up >> showed one vomiting episode in 4 months of treatment with montelukast. >There >> was a decrease in peripheral eosinophilia (574 vs 342 eosinophils/mL) >> compared with baseline 2 months after medications were started. Cromolyn, >> ranitidine, and hydroxyzine were discontinued with no recurrence of >> symptoms. >> >> Tissue injury in eosinophilic gastroenteritis has been shown to correlate >> with the number of activated degranulated eosinophils present.1 Cytokines >> including GM-CSF, IL-3, and IL-5 promote eosinophil proliferation and >> differentiation in the bone marrow as well as being eosinophil chemotaxins >> to sites of inflammation.2 It has been suggested that the release of these >> cytokines with autocrine or paracrine activities by eosinophils in the >> lamina propria of gastrointestinal tissue may lead to the persistent >> eosinophilic infiltration in eosinophilic gastroenteritis.3 Eosinophil >> recruitment may also be enhanced by chemotactic factors such as >> platelet-activating factor, C-C chemokines, and cysteinyl leukotrienes.2 >> Cysteinyl leukotrienes are generated from arachidonic acid through LTC4 >> synthase by mast cells, eosinophils, alveolar macrophages, and basophils, >> leading to end-organ inflammation.2 LTD4 has been shown to be a potent and >> specific chemotactic factor for human eosinophils in vitro, which has been >> completely inhibited by a selective leukotriene antagonist.4 Many factors >> may play a role in directing eosinophils to a site of inflammation. >Because >> LTD4 is both produced by and is a chemotactic factor for eosinophils, this >> may provide the rationale for treating a patient with eosinophilic >> gastroenteritis with a leukotriene receptor antagonist. Further research, >> including double-blind placebo-controlled clinical studies, is needed to >> clarify the potential role leukotrienes play in the inflammation seen in >> eosinophilic gastroenteritis and to assess the potential role for >> leukotriene modifiers in the treatment of this disease. >> >> >> >> >> --------------------------- Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.